The new facility features 24/7 operations, fully automated controls, multiplexed manufacturing lines, and an integrated manufacturing execution system. The facility will produce a range of oligonucleotides, including synthetic single guide RNAs, and has been designed to meet the requirements of both domestic and international regulatory authorities, including the U.S. Food and Drug Administration (FDA) and Health Canada, Synthego said.

The facility also includes dedicated process development, analytical testing, and quality control areas, the company added.

Redwood City, CA-based Synthego offers custom synthetic guide RNAs in three different classes for different stages of the development of CRISPR-enabled therapeutics and diagnostics: research grade, an intermediate "GMP-like" grade, and GMP quality.

"This represents a significant step towards removing industry bottlenecks and helping accelerate access to life-changing and lifesaving CRISPR-enabled cell and gene therapies," Paul Dabrowski, CEO of Synthego, said in a statement.

CRISPR technique cuts time to develop mouse models with any cancer-causing gene
A CRISPR-based technique has cut the time it takes to create mouse models with mutations that cause cancer, making it easier to show the effects of genetic...

CRISPR-Cas9 variant enables DNA cutting at ‘practically any sequence’
Massachusetts General Hospital researchers have engineered a CRISPR-Cas9 variant that overcomes a previous restriction on the locations that DNA can be...

CRISPR technique may lead to hypoallergenic cats
Love cats but have allergies? Rejoice! Scientists have demonstrated that CRISPR gene editing of the cat allergen, Felis domesticus allergen I, could bring...

Intellia, ONK Therapeutics advance CRISPR-edited NK cell therapies for cancer
Intellia Therapeutics and ONK Therapeutics have entered into a licensing and collaboration agreement to develop innovative cancer treatments by combining...

Prime editing shows promise for complex diseases like cystic fibrosis
Researchers have demonstrated that prime editing -- a newer version of CRISPR-Cas9 gene editing -- can be successfully employed to correct gene mutations...

ERS Genomics, GenScript sign CRISPR/Cas9 license deal
ESR Genomics has agreed to nonexclusively license its CRISPR/Cas9 patent portfolio to GenScript.

Synthego debuts CRISPR-based cell engineering platform
Synthego has launched Eclipse, a high-throughput, CRISPR-based cell engineering platform aimed at accelerating drug discovery and validation.

Synthego introduces new CRISPR light control tech
Synthego has designed a new foundational technology for standardized precision and control of CRISPR-based genome editing inside cells using light.